TNGX
Tango Therapeutics, Inc.
There isn't enough reported data to score TNGX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
TNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
TNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
TNGX PE Valuation
TNGX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
TNGX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNGX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | -$0.46 |
| Q2 2026 | -$0.85 | +$0.46 |
| Q1 2026 | -$0.83 | +$0.37 |
| Q4 2025 | -$0.87 | +$0.32 |
| Q3 2025 | -$0.91 | +$0.25 |
| Q2 2025 | -$1.31 | -$0.19 |
| Q1 2025 | -$1.20 | -$0.09 |
| Q4 2024 | -$1.19 | -$0.11 |
TNGX lost $1.37 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over TNGX on earnings quality, reporting a profit while its opponent remains loss making.
TNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $53.8M | +364% |
| Q2 2025 | $3.2M | -84% |
| Q1 2025 | $5.4M | -17% |
| Q4 2024 | $4.1M | -24% |
| Q3 2024 | $11.6M | +8.2% |
| Q2 2024 | $19.9M | +36% |
| Q1 2024 | $6.5M | +12% |
| Q4 2023 | $5.4M | -15% |
TNGX's revenue has slid since its 2025 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | 26% | +309 points |
| Q2 2025 | -1288% | -1139 points |
| Q1 2025 | -789% | -136 points |
| Q4 2024 | -994% | -349 points |
| Q3 2024 | -283% | -45 points |
| Q2 2024 | -149% | +11 points |
| Q1 2024 | -653% | -128 points |
| Q4 2023 | -645% | -168 points |
TNGX's operating margin was 26% last quarter, up 309 points from the same quarter a year ago, near the top of its range since 2020.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over TNGX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
TNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | -$6.1M |
| Q2 2026 | -$38.9M | -$1.7M |
| Q1 2026 | -$44.4M | -$2.6M |
| Q4 2025 | -$29.9M | +$6.8M |
| Q3 2025 | -$31.1M | +$2.4M |
| Q2 2025 | -$37.1M | -$13.2M |
| Q1 2025 | -$41.7M | -$3.7M |
| Q4 2024 | -$36.8M | -$9.1M |
TNGX has burned cash in almost every quarter: −$150M over the past year, against −$147M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over TNGX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNGX Net Leverage
TNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
TNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 27.6 | Neutral |
TNGX's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
TNGX PE vs Healthcare Sector
TNGX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
TNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.3 | 6.7% above |
| 20 week MA | $24.9 | 0% below |
| 50 week MA | $20.5 | 21% above |
| 100 week MA | $12.6 | 97% above |
| 200 week MA | $9.89 | 151% above |
TNGX's trend is mixed: it's above four of its five weekly moving averages, and 151% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
TNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $11.3 | +9.9% |
| 2021 | $11.3 | $10.9 | -2.8% |
| 2022 | $10.9 | $7.83 | -28% |
| 2023 | $7.83 | $9.90 | +26% |
| 2024 | $9.90 | $3.12 | -68% |
| 2025 | $3.12 | $8.67 | +178% |
| 2026 YTD | $8.67 | $24.9 | +187% |
TNGX has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.